伊人久久大香线蕉AV影院,情侣国产一二三区视频观看,香蕉丝瓜榴莲在线观看√天堂资源中文官网,日韩精品无码观看视频免费,亚洲伊人成无码综合网欧美亚洲综合在线一区,国产午夜精品视频一区二区三区,亚洲毛片在线日韩无码大乱交,国产精品国产三级欧美二区

R&D
Manufacturing
Commericalization
R&D
Comprehensive Strength

Mabwell has established an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation. The international standard drug discovery platforms and skillful & efficient development platforms enable us to develop innovative biologics efficiently and submit IND rapidly. We focus on large-scale, fast-growing therapeutic areas including oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Mabwell has 15 pipeline products. Of these, 3 products have been approved and commercialized, 1 product is undergoing market approval review, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects.

?
?
Manufacturing
International Standard of Intelligent Manufacturing

Compliant with GMP requirements in China, U.S., and EU
Integrated production capacity of monoclonal antibodies, fusion proteins, ADCs and other drug molecules to support clinical research and commercial manufacturing
Transparent factory, penetrating supervision, permeable management, flexible production

Taizhou, Jiangsu Pilot & Commercial Manufacturing Site

EU QP Audited

Capacity

8,000L, antibody production; 4,000L, recombinant protein production

2 drug product filling lines for pre-filling syringes & vials

Production

Undertaking production of MAILISHU & MAIWEIJIAN

Taizhou, Jiangsu Large Scale ADC Commercial Manufacturing Site

Area

~53,400 ㎡

ADC production

Capable of providing drug samples for pre-clinical & early phase clinical use

Scaling up production in the kilogram can meet the needs of pivotal trials to commercialization

QA & QC (under construction)

Ready for trial production

Shanghai Large Scale Commercial Manufacturing Site

Capacity

Total planned capacity of 27,000L (stage I)

Digitalization

Distributed Control System greatly improves the automation of liquid preparation process

Full-automatic 3D warehouse to meet smart inventory management

The integration of automation and informatization to achieve digitalization

Commercialization

Market led, Medical-driven, Access first

Deeply engaged in academic promotion in autoimmune diseases, osteoporosis and oncology, we have built mature and professional marketing network in China, bringing world-class novel therapeutic options to more domestic patients. Our marketing management team is led by professionals with over 20 years of experience in average.


Improve Global Health

We are expanding to Euramerican market and emerging markets to meet the clinical needs of patients worldwide, and have entered into strategic partnerships with more than a dozen countries overseas.


License out

2023.1 - Entered into an agreement with DISC MEDICINE (NASDAQ: IRON) about 9MW3011 (R&D code in the US: MWTX-001, MWTX-002 & MWTX-003) with a total of up to $412.5 million of down payment and milestone payment.


Partnership in emerging market

Get in touch with our BD team: ib@mabwell.com


2024.11 - Established a licensing and commercialization agreement of denosumab products in Peru

2024.8 - Established a Licensing and Commercialization agreement of denosumab products with CRISTáLIA in Brazil

2024.1 - Established a licensing and commercialization agreement to market of denosumab products in Indonesia

2023.11 - Established partnership with Innobic (wholly owned subsidiary of PTT Public Company Ltd, the state-owned enterprise and the largest company by market capitalization on Thailand Stock Exchange) to market products in Thailand

2023.10 - Established partnership with UPL to market 9MW0113 in Argentina

2023.9 - Established partnership with Legrand to market 9MW0311 & 9MW0321 in Colombia and Ecuador

2023.8 - Established partnership with UNILAB (ranks number 1 in the ASEAN pharmaceutical industry) to market 9MW0113 in the Philippines

2023.7 - Established partnership with Sothema (the biggest pharmaceutical company in Morocco) to market 9MW0113 in Morocco 

2023.7 - Established partnership with Searle (one of the top pharmaceutical companies in Pakistan) to market 9MW0311 & 9MW0321 in Pakistan

2023.6 - Established a licensing and commercialization agreement of 9MW0311 & 9MW0321 for Egypt market 

曰本丰满熟妇XXXX性| 国产成人综合日韩精品无码| 国产精品久久久久久久午夜片| 色婷婷五月激情中文字幕| 亚洲另类自拍丝袜第1页| 激情国产精品视频一区二区| 婷婷综合缴情亚洲狠狠尤物| 亚洲AV永久无码精品黑人| 99精品视频免费热播在线观看| 18禁在线无遮挡免费观看网站| 久久久精品日本一区二区三区| 国产在线观看一区精品| 国产99视频精品免费观看6| 亚洲2022国产成人精品无码区| 色桃花亚洲天堂视频久久| 国产在线精品观看一区欧美| 亚洲国产韩国欧美在线| 好男人高清免费观看日本| 日韩AV无码精品一二三区| 毛多水多高潮高清视频| 日本一区二区三区不卡免费| 日韩久久精品一级精品电影| 日本理论电影久久网| 亚洲精品无码乱码成人| 国产放荡AV剧情演绎麻豆| 国产级毛片国语版普通语| 国产偷v国产偷v亚洲高清| 国产乱子伦对白视频免费| 97精品久久久久中文字幕| 亚洲欧美国产精品久久| 无码人妻精品一区二区| 亚洲国产精品第一区二区| 不卡AV片在线看| 一边摸一边抽搐一进一出视频| 国产乱码一二三区精品| 日韩欧美国产亚洲另类| 囯产免费久久久久久国产免费| 天堂Av无码Av日韩Av国产在线观看流白浆| 国产精品成人午夜电影| 欧美大片欧美激情性色a∨在线| 在线中文天堂最新版www|